Biotech Licenses Technology for Colorectal Cancer Blood Test

(James. J. Caras, NSF)

Epigenomics AG in Berlin, Germany says it has an agreement for QIAGEN NV in the Netherlands to further develop Epigenomics’s research into a blood test for colorectal cancer. QIAGEN also has an option under the agreement to take the blood test to market.

The technology is based on Epigenomics’s research into genomics and DNA indicators of cancer. The company says that numerous studies have shown a correlation between the Septin9 biomarker in blood plasma and the presence of colorectal cancer, and thus can be used to help detect this common cancer. A blood test that is more convenient for the patients than stool tests or a colonoscopy could encourage more people to be screened.

QIAGEN is a developer of technologies to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. The company also makes assay technologies to make such isolated bio-molecules visible.

Under the agreement, Epigenomics will receive an initial payment from QIAGEN and reimbursement for R&D support and clinical specimens provided during the R&D phase. If QIAGEN exercises the option to commercialize the test, Epigenomics would receive a further license payment. Once QIAGEN takes a colorectal cancer blood test to market based on Epigenomics’ biomarkers and technology, Epigenomics would be entitled to royalties on QIAGEN’s net sales and milestone payments.

Read more: Genetic Signature Validated for Early-Stage Colon Cancer

*     *     *